Abstract:Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all, human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms: mutation of the gene leading to an absence of tumour suppressor activity and, in some cases, gain-of-oncogenic function; or inhibition of the wild-type p53 protein mediated by overexpression of its negative regulators MDM2 and MDMX. Because of its high potency as a tumour suppressor and the dependence of at least some established tumours on its inactivation, p53 appears to be a highly attractive target for the development of new anticancer drugs. However, p53 is a transcription factor and therefore has long been considered undruggable. Nevertheless, several innovative strategies have been pursued for targeting dysfunctional p53 for cancer treatment. In mutant p53-expressing tumours, the predominant strategy is to restore tumour suppressor function with compounds acting either in a generic manner or otherwise selective for one or a few specific p53 mutations. In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by targeting these negative regulators with inhibitors. Although the results of at least some clinical trials of MDM2 inhibitors and mutant p53-restoring compounds are promising, none of the agents has yet been approved by the FDA. Alternative strategies, based on a better understanding of p53 biology, the mechanisms of action of compounds and treatment regimens as well as the development of new technologies are gaining interest, such as proteolysis-targeting chimeras for MDM2 degradation. Other approaches are taking advantage of the progress made in immune-based therapies for cancer. In this Review, we present these ongoing clinical trials and emerging approaches to re-evaluate the current state of knowledge of p53-based therapies for cancer.

Targeting mutant p53 for efficient cancer therapy

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Translating p53-based therapies for cancer into the clinic

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Targeting P53 for Novel Anticancer Therapy.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Mutant p53 in Cancer Progression and Targeted Therapies

Therapeutic targeting of p53 by small molecules

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

Targeting mutant p53 stabilization for cancer therapy

Drugging p53 in cancer: one protein, many targets

Anticancer therapeutic strategies for targeting mutant p53-Y220C

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors

Activating p53 with a Mutant-Specific Small Molecule

The Development of P53-Targeted Therapies for Human Cancers

Restoration of p53 to limit tumor growth